Format

Send to

Choose Destination
See comment in PubMed Commons below
Vasc Health Risk Manag. 2010 Aug 9;6:465-72.

Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia.

Author information

1
Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Canada.

Abstract

Amiodarone has emerged as the leading antiarrhythmic therapy for termination and prevention of ventricular arrhythmia in different clinical settings because of its proven efficacy and safety. In patients with shock refractory out-of-hospital cardiac arrest and hemodynamically destabilizing ventricular arrhythmia, amiodarone is the most effective drug available to assist in resuscitation. Although the superiority of the transvenous implantable cardioverter defibrillator (ICD) over amiodarone has been well established in the preventive treatment of patients at high risk of life-threatening ventricular arrhythmias, amiodarone (if used with a beta-blocker) is the most effective antiarrhythmic drug to prevent ICD shocks and treat electrical storm. Both the pharmacokinetics and the electrophysiologic profile of amiodarone are complex, and its optimal and safe use requires careful patient surveillance with respect to potential adverse effects.

KEYWORDS:

amiodarone; unstable ventricular tachycardia; ventricular fibrillation

PMID:
20730062
PMCID:
PMC2922307
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center